Companion Animal Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Animal Type (Dogs, Cats, Horses, Others), By Vaccine Type (Attenuated Live Vaccines, inactivated (Killed) Vaccines, Recombinant Vaccines, Toxoid Vaccines, Others), By End User (Rabies, Canine Distemper, Canine Parvovirus, Feline Leukemia, Feline Calicivirus, Others) and Region Forecast 2020-2031

Companion Animal Vaccine Market size was valued at US$ 4,015.2 million in 2024 and is projected to reach US$ 7,061.7 million by 2031 at a CAGR of 8.4% from 2025-2031. Moreover, the U.S Companion Animal Vaccine Market is projected to grow at a CAGR of 8.3% over the forecast period.

The market refers to the segment of the veterinary healthcare industry that develops, manufactures, and distributes vaccines aimed at preventing infectious diseases in pets such as dogs, cats, horses, and other domesticated animals. These vaccines enhance immunity, safeguard animal health, reduce the spread of zoonotic diseases, and support the overall well-being of animals within human households.

The market is witnessing steady growth, driven by rising pet ownership, increasing awareness of preventive healthcare, and the humanization of pets. Advancements in biotechnology, combined with growing veterinary infrastructure and supportive government initiatives for zoonotic disease control, further accelerate demand. However, challenges such as high R&D costs, stringent regulatory pathways, and limited vaccine coverage for emerging diseases continue to shape the competitive landscape.

Facts & Figures

• In fact, Rabies burden: According to WHO, rabies causes over 59,000 human deaths annually, with 99% of cases linked to dog-transmitted rabies, highlighting the critical need for pet vaccination.
• Pet ownership: In the U.S., nearly 66% of households (about 87 million homes) own a pet, with dogs and cats being the most common.
• Global dog population: There are an estimated 470 million pet dogs worldwide, representing the largest vaccinated companion animal group.
• Feline vaccines: The global domestic cat population is estimated at 370 million, with vaccination coverage steadily increasing in both developed and emerging markets.
• Rabies elimination goal: The WHO, WOAH, and partners aim for “Zero human deaths from dog-mediated rabies by 2030”, driving large-scale vaccination programs globally.
• Veterinary spending: In 2023, U.S. pet owners spent over $38 billion on veterinary care and products, a substantial portion of which included preventive services such as vaccinations.

Key Developments

• In September 2024, Bioveta, a.s. announced a strategic partnership with Vetina Healthcare LLP to enter the Indian market. Through this collaboration, they are introducing the Biocan NOVEL vaccine range, a portfolio with a proven track record spanning over a decade.
• In March 2024, Zendal Group launched a vaccine against canine leishmaniasis, developed in collaboration with CSIC, making it available to the market.

Companion Animal Vaccines Market Segmentation

Based on the animal type

• Dogs
• Cats
• Horses
• Others

Based on animal type, dogs are anticipated to lead the companion animal vaccine market, primarily due to their significantly higher ownership rates worldwide compared to other companion animals. Dogs are often regarded as family members, which drives owners to prioritize preventive healthcare, particularly vaccination against rabies, distemper, parvovirus, and other infectious diseases. A key driver of this leadership is the mandatory rabies vaccination programs enforced by governments across many countries, as rabies remains a critical zoonotic threat. Additionally, the growing availability of canine-specific insurance plans and wellness programs further boosts vaccine adoption, reinforcing dogs as the dominant segment in the market.

Based on the vaccine type

• Attenuated Live Vaccines
• Inactivated (Killed) Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

Based on vaccine type, attenuated live vaccines are anticipated to lead the companion animal vaccine market, owing to their high efficacy and ability to provide long-lasting immunity with fewer doses. These vaccines contain weakened forms of pathogens that stimulate a strong and durable immune response in animals, making them a preferred choice among veterinarians for preventing common diseases in dogs, cats, and horses. A major driver for this dominance is the widespread use of live vaccines in rabies, canine distemper, and feline calicivirus immunization programs. Their cost-effectiveness and proven safety record further strengthen their adoption, positioning attenuated live vaccines as the leading segment in the market.

Based on the application

• Rabies
• Canine Distemper
• Canine Parvovirus
• Feline Leukemia
• Feline Calicivirus
• Others

Based on application, rabies vaccine segment is anticipated to lead the companion animal vaccine market, primarily due to the global emphasis on controlling and eliminating rabies as a fatal zoonotic disease. Rabies vaccination is often mandated by government regulations in both developed and developing countries, ensuring consistent and large-scale adoption among pet owners, particularly for dogs and cats. International initiatives led by the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH) also support widespread rabies vaccination campaigns, especially in Asia and Africa, where rabies prevalence remains high. This strong regulatory push and life-saving significance position rabies vaccines as the dominant segment in the market.